Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting
Current TAP Partner
PHILADELPHIA, PA – April 14, 2023 – Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting held from Friday, April 14 – Wednesday, April 19 in Orlando, FL. The accepted data reinforce the potential of Carisma’s differentiated and proprietary cell therapy platform focused on engineered macrophages as a novel treatment pathway for hard-to-treat cancers and other serious illnesses.
Tuesday, April 18 at 9:00 am ET: Macrophages engineered with cytokine switch receptors: Development of a modular platform for rebalancing inflammation in microenvironments
Tuesday, April 18 at 9:00 am ET: A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119
Tuesday, April 18 at 1:30 pm ET-5:00 pm ET: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors